General characteristics of the study population
| Clinical characteristics | Total population | Group A (<65 yrs) | Group B (≥65 yrs) | p |
|---|---|---|---|---|
| N (%) | N=96 | N=70 | N=26 | |
| Sex: (M/F) | 43/53 | 31/39 | 12/14 | ns |
| (44.79%/55.21%) | (44.28%/55.71%) | (46.15%/53.84%) | ||
| Type of AAV: | ||||
| EGPA | 55 (57.29%) | 38 (39.59%) | 17 (17.71%) | ns |
| GPA | 38 (39.58%) | 29 (41.43%) | 9 (9.37%) | 0.006 |
| MPA | 3 (3.12%) | 3 (4.29%) | 0 | ns |
| p-ANCA (MPO) | 33 (34.37%) | 22 (40.43%) | 11 (42.31%) | ns |
| c-ANCA (PR3) | 28 (29.17%) | 25 (35.71%) | 3 (11.54%) | 0.03 |
| FFS positivity | 37 (38.54%) | 28 (40%) | 9 (34.61%) | ns |
| BVAS at onset (mean ± SD) | 14.83±7.57 | 14.60±7.67 | 15.46±7.17 | ns |
| BVAS at the end of follow up (mean ± SD) | 1.52±1.85 | 1.68±1.93 | 1.09±1.57 | ns |
| VDI at the end of follow up (mean ± SD) | 1.24±1.07 | 1.30±1.08 | 1.08±1.04 | ns |
FFS: Five Factor Score, BVAS: Birmingham Vasculitis Activity Score, VDI: Vasculitis Damage Index.